Shots:

• AM-Pharma to receive $23.6M up front- $35.4M in milestones before regulatory submission and ~$230.4M upon submission- NHI price listing & sales milestone along with royalties on sales and a drug supply fee
• Kyowa Kirin to get the exclusive right to develop and commercialize ilofotase alfa in Japan. Ilofotase alfa is currently being evaluated in a P-III REVIVAL study in 1600 patients with SA-AKI
• AM-Pharma is responsible for the completion of the P-III REVIVAL study & P-I PK- safety- and tolerability study in Japan. Kyowa Kirin will lead the regulatory approval process and commercialization of ilofotase alfa in Japan

| Ref: Business wire | Image: Kyowa Kirin